Payment overview · 2025
General Payments
$254.75
11 reported records · 10 companies
Healthcare provider profile · identity verified
Kristina Carpenter, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · CONCORD, CA · NPI 1952741985
Verified facts
What the public records show
CMS Open Payments records show Kristina Carpenter, D.O. received $254.75 in general payments during 2025 across 11 reported records.
ABBVIE INC. accounted for 21.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Synthroid by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $53.50 | 21.0% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $34.61 | 13.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $30.51 | 12.0% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $27.64 | 10.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $25.70 | 10.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $25.30 | 9.9% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $17.27 | 6.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.08 | 6.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.05 | 6.7% | 1 | 2025 |
| MAYNE PHARMA COMMERCIAL LLC | Unresolved — no canonical attribution shown | $6.09 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $254.75 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $53.50 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $34.61 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $34.61 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $30.51 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $27.64 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $25.70 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $25.30 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.08 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| REXULTI rexulti |
2025 | Rexulti | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 302 | 88 |
| Levothyroxine Sodium | Levothyroxine Sodium | 216 | 55 |
| Trazodone Hcl | Trazodone Hcl | 157 | 35 |
| Lisinopril | Lisinopril | 143 | 42 |
| Amlodipine Besylate | Amlodipine Besylate | 136 | 44 |
| Gabapentin | Gabapentin | 118 | 42 |
| Metformin Hcl | Metformin Hcl | 112 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 91 | 24 |
| Simvastatin | Simvastatin | 84 | 26 |
| Losartan Potassium | Losartan Potassium | 82 | 27 |
| Celecoxib | Celecoxib | 72 | 24 |
| Sertraline Hcl | Sertraline Hcl | 71 | 17 |
| Omeprazole | Omeprazole | 63 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 61 | 18 |
| Furosemide | Furosemide | 60 | 23 |
| Allopurinol | Allopurinol | 59 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 59 | 11 |
| Famotidine | Famotidine | 56 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 56 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 55 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 52 | 16 |
| Jardiance | Empagliflozin | 51 | suppressed |
| Bupropion Xl | Bupropion Hcl | 50 | 12 |
| Mirtazapine | Mirtazapine | 48 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 47 | suppressed |
| Eliquis | Apixaban | 46 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 46 | 15 |
| Pantoprazole Sodium | Pantoprazole Sodium | 40 | 14 |
| Ibuprofen | Ibuprofen | 38 | 12 |
| Azelastine Hcl | Azelastine Hcl | 37 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 36 | 13 |
| Montelukast Sodium | Montelukast Sodium | 34 | suppressed |
| Lorazepam | Lorazepam | 32 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 27 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 27 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Potassium Chloride | Potassium Chloride | 23 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | suppressed |
| Rexulti | Brexpiprazole | 22 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Clonazepam | Clonazepam | 20 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 19 | suppressed |
| Carvedilol | Carvedilol | 19 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Prednisone | Prednisone | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Ozempic | Semaglutide | 14 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Klor-Con M15 | Potassium Chloride | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $254.75 · 11 records | ABBVIE INC. | Cologuard Collection Kit, FANAPT, FARXIGA, HETLIOZ, REXULTI, SHINGRIX, SUBLOCADE, VRAYLAR, Wegovy, XIFAXAN | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rexulti play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error